Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK’s Advair® Diskus® achieves primary endpoint in LABA safety study of patients with asthma
GlaxoSmithKline plc (GSK) today announced results from the ‘LABA’ (long acting beta2-agonist) safety study, AUSTRI (SAS115359).
-
GSK receives CHMP positive opinion to expand indication for Volibris® in pulmonary arterial hypertension
GSK receives CHMP positive opinion to expand indication for Volibris® in pulmonary arterial hypertension
-
GSK announces positive new data comparing Incruse® Ellipta® to tiotropium and glycopyrronium in patients with COPD
GSK announced positive results from comparing umeclidinium to two available bronchodilator treatments when used by patients with COPD.
-
GSK submits regulatory application for chlorhexidine gel for the prevention of umbilical cord infections in newborn babies
GSK announced it's submitted an application to EMA for antiseptic chlorhexidine gel for the prevention omphalitis in newborn babies.
-
GSK presents post-hoc analysis of Anoro® Ellipta® data assessing markers of COPD deterioration compared to tiotropium or placebo using a novel composite endpoint
GSK and THRX today announced data presented by GSK at the European Respiratory Society (ERS) International Congress (poster PA1001)
-
Regulatory update: GSK and Theravance announce intention to file Relvar® Ellipta® for COPD in Japan
GSK and THRX announced intention to file sJNDA for Relvar® Ellipta® for the treatment of COPD with the Japanese authority during the Q12016.
-
GSK receives positive CHMP opinion in Europe for novel anti-IL5 biological Nucala (mepolizumab) for the treatment of patients with severe refractory eosinophilic asthma
GSK today announced that the CHMP of EMA issued a positive opinion recommending marketing authorisation for mepolizumab
-
New Phase IIIb/IV data show switching to once-daily Triumeq® maintains HIV viral suppression
ViiV Healthcare today announced 24-week data from the Phase IIIb/IV STRIIVING study
-
GSK starts build of its largest Indian tablet manufacturing pharmaceutical factory in Vemgal, Karnataka
Hon’ble Chief Minister of Karnataka, Shri Siddaramaiah lays the foundation stone of the new pharmaceutical factory
-
GSK and Theravance announce results from the SUMMIT COPD CV Survival Study
GSK and THRX announced initial results from study for Relvar®Breo® Ellipta® 100/25mcg (fluticasone furoate ‘FF’/vilanterol ‘VI’ or ‘FF/VI’).
-
GSK announces NEJM publication of Phase 3b/4 study of ambrisentan and tadalafil as first-line combination treatment in patients with pulmonary arterial hypertension
GSK today announced publication of first-line combination therapy of ambrisentan and tadalafil in treatment-naïve patients with PAH.
-
GSK to divest ofatumumab for auto-immune indications to Novartis for up to $1 billion plus royalties
GSK announced an agreement with Novartis Pharma to divest its rights in ofatumumab for auto-immune indications, incl. multiple sclerosis.
-
Results Announcement for the second quarter 2015
GSK delivers Q2 Group sales of £5.9 billion +7% CER and core EPS of 17.3p (flat CER) in first full quarter of performance since transaction
-
GSK’s Synflorix™ receives CHMP positive opinion for major label extension
GSK announced that the CHMP of EMA has issued a positive opinion for the expansion of the SynflorixTM European label
-
GSK’s malaria candidate vaccine, Mosquirix™ (RTS,S), receives positive opinion from European regulators for the prevention of malaria in young children in sub-Saharan Africa
GSK announced that the CHMP of EMA has adopted a positive scientific opinion for its malaria candidate vaccine Mosquirix.
-
GSK and Save the Children launch 2015 call for developing country healthcare innovations to reduce child deaths
GSK and Save the Children announce the launch of their third annual $1 million Healthcare Innovation Award.
-
GSK and the Francis Crick Institute join forces in collaboration to forge new scientific discoveries
The Francis Crick Institute and GSK to partner on an innovation collaboration exploring new avenues of medical research and drug discovery
-
Regulatory update on divestment of Nimenrix and Mencevax
GSK is divesting its meningitis vaccines Nimenrix and Mencevax to Pfizer Ireland Pharmaceuticals (a subsidiary of Pfizer Inc).
-
GSK to create independent research institute with goal of radically changing and improving medicines development
Seattle-based Altius Institute for Biomedical Sciences to pioneer new understanding of cell “operating systems”
-
GSK announces outcome of US FDA Advisory Committee recommending approval of mepolizumab for the treatment of adults with severe asthma
GSK announced outcome regarding the BLA for mepolizumab as an add-on maintenance treatment for severe asthma with eosinophilic inflammation.
